BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority By: Reuters: Company News January 25, 2018 at 10:02 AM EST * CELGENE CEO SAYS WORKING WITH BLUEBIRD BIO TO DEVELOP BB2121 CAR-T THERAPY FOR MYELOMA REMAINS A TOP PRIORITY Read More >> Related Stocks: Bluebird Bio Celgene Corp